Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?
作者信息
Tannapfel Andrea, Reinacher-Schick Anke
机构信息
Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.
Department of Hematology, Oncology and Palliative Care, Ruhr-University Bochum, Bochum, Germany.
出版信息
Visc Med. 2019 Mar;35(1):1-2. doi: 10.1159/000497294. Epub 2019 Feb 8.
Abstract
摘要
相似文献
1
Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?胃肠道癌的免疫疗法：我们目前的进展如何？
Visc Med. 2019 Mar;35(1):1-2. doi: 10.1159/000497294. Epub 2019 Feb 8.
2
Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?放疗联合免疫治疗宫颈癌：现状与未来
Curr Treat Options Oncol. 2023 Oct;24(10):1378-1391. doi: 10.1007/s11864-023-01128-6. Epub 2023 Aug 3.
3
Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.我们在结直肠癌免疫治疗中的立场：错配修复缺陷、错配修复 proficient 及毒性管理
Am Soc Clin Oncol Educ Book. 2018 May 23;38:239-247. doi: 10.1200/EDBK_200821.
4
Immunotherapy and immunoprevention of cancer: where do we stand?癌症的免疫治疗与免疫预防：我们目前的进展如何？
Expert Opin Biol Ther. 2005 May;5(5):717-26. doi: 10.1517/14712598.5.5.717.
5
Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?局部晚期头颈部癌症的化放疗和免疫治疗：我们的现状如何？
Oral Oncol. 2022 Apr;127:105773. doi: 10.1016/j.oraloncology.2022.105773. Epub 2022 Feb 24.
6
Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?肝细胞癌的局部区域治疗联合免疫疗法：我们目前的进展如何？
Future Oncol. 2022 May;18(14):1665-1668. doi: 10.2217/fon-2021-1623. Epub 2022 Feb 23.
7
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?化疗联合单药/双药免疫疗法治疗非癌基因成瘾性晚期非小细胞肺癌：我们现状如何，又将走向何方？
Expert Rev Anticancer Ther. 2022 Feb;22(2):183-189. doi: 10.1080/14737140.2022.2026772. Epub 2022 Jan 20.
8
Evaluating response to immunotherapy with F-FDG PET/CT: where do we stand?用F-FDG PET/CT评估免疫治疗反应：我们目前的进展如何？
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1019-1021. doi: 10.1007/s00259-020-04702-4.
9
Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?子宫内膜癌干细胞：我们处于何处，又应走向何方？
Int J Mol Sci. 2022 Mar 21;23(6):3412. doi: 10.3390/ijms23063412.
10
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?癌睾丸抗原与免疫疗法：我们在针对黑色素瘤优先表达抗原（PRAME）的靶向治疗方面进展如何？
Cancers (Basel). 2019 Jul 15;11(7):984. doi: 10.3390/cancers11070984.
引用本文的文献
1
The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review).免疫原性细胞死亡在胃肠道癌免疫治疗中的作用（综述）
Biomed Rep. 2021 Oct;15(4):86. doi: 10.3892/br.2021.1462. Epub 2021 Aug 17.
本文引用的文献
1
Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer.免疫疗法：胰腺癌和肝外胆管癌
Visc Med. 2019 Mar;35(1):28-37. doi: 10.1159/000497291. Epub 2019 Feb 7.
2
Implications of Immunotherapy in Hepatobiliary Tumors.免疫疗法在肝胆肿瘤中的应用
Visc Med. 2019 Mar;35(1):18-26. doi: 10.1159/000496755. Epub 2019 Feb 8.
3
Immunotherapy in Esophagogastric Adenocarcinoma.食管胃腺癌的免疫治疗
Visc Med. 2019 Mar;35(1):12-16. doi: 10.1159/000497292. Epub 2019 Feb 7.
4
Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer.胃肠道癌免疫生物标志物及免疫疗法生物标志物
Visc Med. 2019 Mar;35(1):3-10. doi: 10.1159/000496565. Epub 2019 Feb 4.
5
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.曲妥珠单抗联合化疗与单纯化疗治疗 HER2 阳性晚期胃或胃食管交界腺癌（ToGA）：一项开放标签、随机对照的 3 期临床试验。
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
6
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.西妥昔单抗与化疗联合作为转移性结直肠癌的初始治疗方案
N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
7
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.一种新型B7家族成员与PD-1免疫抑制受体的结合导致淋巴细胞活化的负调节。
J Exp Med. 2000 Oct 2;192(7):1027-34. doi: 10.1084/jem.192.7.1027.
8
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.人类胃肠道间质瘤中c-kit的功能获得性突变。
Science. 1998 Jan 23;279(5350):577-80. doi: 10.1126/science.279.5350.577.
9
Enhancement of antitumor immunity by CTLA-4 blockade.通过阻断CTLA-4增强抗肿瘤免疫力。
Science. 1996 Mar 22;271(5256):1734-6. doi: 10.1126/science.271.5256.1734.
Zotero 插件